Latest News

Unleashad

European_Commission.svg

TILT won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument. The grant will be used to perform a Phase 1 clinical trial with the company’s lead drug, TILT-123. Read the press release here.

Latest News

Upcoming Events

Please contact our business development team to meet us at the following events:

April 25-30, 2025
Chicago (IL), USA
May 30 - June 3, 2025
Chicago (IL), USA
May 20-21, 2025
Bergen, Norway
June 16-19, 2025
Boston (MA), USA